Table 1 Correlation between Sirt6 expression and clinical characteristics of DLBCL patients
Characteristics | No. of patients | Sirt6 expression | p value | |
|---|---|---|---|---|
Negative | Positive (%) | Â | ||
Age(years) | ||||
 <60 | 41 | 13 | 28(68.3%) | 0.009 |
  ≥ 60 | 29 | 1 | 28(96.6%) |  |
Gender | ||||
 Male | 34 | 6 | 28(82.4%) | 0.858 |
 Female | 36 | 8 | 28(77.8%) |  |
Ann Arbor stage | ||||
 I or II | 35 | 11 | 24(68.6%) | 0.036 |
 III or IV | 35 | 3 | 32(91.4%) |  |
B symptoms | ||||
 Present | 17 | 2 | 15(88.2%) | 0.531 |
 Absent | 53 | 12 | 41(77.4%) |  |
Sybtype | ||||
 GCB | 22 | 6 | 16(72.7%) | 0.479 |
 Non-GCB | 48 | 8 | 40(83.3%) |  |
Serum LDH | ||||
 Normal | 28 | 9 | 19(67.9%) | 0.077 |
 Elevated | 42 | 5 | 37(88.1%) |  |
Extranodal involvement | ||||
 Absent | 14 | 2 | 12(85.7%) | 0.823 |
 Present | 56 | 12 | 44(78.6%) |  |
IPI score | ||||
 0–2 | 41 | 12 | 29(70.7%) | 0.045 |
 3–5 | 29 | 2 | 27(93.1%) |  |